CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
CORT$73.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Product revenue, net | $482,375 | $401,858 | $365,978 |
| Operating expenses: | |||
| Cost of sales | 6,481 | 5,385 | 5,281 |
| Research and development | 184,353 | 130,991 | 113,864 |
| Selling, general and administrative | 184,259 | 152,848 | 122,356 |
| Settlement expense related to Melucci litigation | — | 14,000 | — |
| Insurance recovery related to Melucci litigation | — | (14,000) | — |
| Total operating expenses | 375,093 | 289,224 | 241,501 |
| Income from operations | 107,282 | 112,634 | 124,477 |
| Interest and other income | 17,275 | 3,557 | 529 |
| Income before income taxes | 124,557 | 116,191 | 125,006 |
| Income tax expense | (18,417) | (14,773) | (12,494) |
| Net income | $106,140 | $101,418 | $112,512 |
| Net income attributable to common stockholders | $105,496 | $101,288 | $112,512 |
| Basic net income per common share | $1.02 | $0.95 | $0.97 |
| Diluted net income per common share | $0.94 | $0.87 | $0.89 |
| Weighted-average shares outstanding used in computing net income per common share | |||
| Basic | 103,560 | 106,787 | 115,653 |
| Diluted | 111,742 | 115,966 | 125,963 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.